AUTL News and Press, Autolus Therapeutics plc From 10/21/22

LONDON, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it will release its third quarter 2022 financial results and operational highlights...

Autolus Therapeutics ( NASDAQ: AUTL ) said Moderna ( NASDAQ: MRNA ) exercised an option to license AUTL's proprietary binders against an undisclosed immuno-oncology target to develop and commercialize mRNA therapeutics. Autolus ( AUTL ) received an option e...

- Option exercised on undisclosed immune-oncology target following evaluation period by Moderna - - Autolus receives option exercise fee, with potential for development milestone payments plus royalties - LONDON, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc&#...

Summary Due to an extended downtrend in Athersys stock price due largely to a declining cash position, Athersys currently trades at a market cap near $24 million. The current valuation is miniscule when compared to valuations of other stem cell companies, especially when consideri...

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all cancer-related deaths worldwide. Of concern, despite treatmen...

- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option exercise fees and development milestone payments plus royalties - LONDON, Oct. 04, 2...

BETHESDA, Md., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational discovery platform identifying novel allosteric binding sit...

Shares of AUTL have lost a third of their value over the past year. Sentiment in the autologous CAR-T space is improving as lead players successfully grow sales and scale up to meet demand. Obe-cel's lead opportunity in adult ALL is attractive relative to current enterprise value ...

Autolus Therapeutics plc (AUTL) Q2 2022 Earnings Conference Call August 04, 2022, 08:30 AM ET Company Participants Olivia Manser - Director, IR Christian Itin - CEO Lucinda Crabtree - CFO Conference Call Participants Mara Goldstein - Mizuho Rob An...

Autolus Therapeutics press release ( NASDAQ: AUTL ): Q2 GAAP EPS of -$0.46 misses by $0.13 . Cash at Q2 totaled $216.4 million, as compared to cash of $310.3 million at December 31, 2021. For further details see: Autolus Therapeutics GAAP EPS of -$0.46 misses...